Opko Health (NASDAQ: OPK)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Opko Health Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Opko Health Company Info
Opko Health Inc. is engaged in the development and commercialization of pharmaceutical products vaccines diagnostic technologies and imaging systems.
News & Analysis
A major pharma name is showing interest in one of the company's vaccine prospects.
Investors shrugged off the company's notably worse-than-expected quarterly results.
The company topped Q1 revenue estimates and announced a key new acquisition.
A bottom-line earnings miss adds to a general bearishness on coronavirus stocks.
The FDA refused to approve human growth hormone somatrogon.
The market was counting on a key drug approval that suddenly appears unlikely to happen.
The coronavirus stock didn't impress with its Q2 results.
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.
We said what? Let’s face it: Sometimes our predictions miss the mark, and with Rite Aid and Opko Health, they missed the mark by a lot. Here’s what we said, why we said it, and what we learned from our mistakes.
These been-there-done-that leaders are at the helm of four different emerging companies that investors should be paying attention to.
OPK earnings call for the period ending December 31, 2022.
OPK earnings call for the period ending September 30, 2022.
OPK earnings call for the period ending June 30, 2022.
OPK earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.